Display options
Cite
Kragstrup TW, Sohn DH, Lepus CM, et al. Fibroblast-like synovial cell production of extra domain A fibronectin associates with inflammation in osteoarthritis. BMC Rheumatol. 2019;3:46doi: 10.1186/s41927-019-0093-4.
Kragstrup, T. W., Sohn, D. H., Lepus, C. M., Onuma, K., Wang, Q., Robinson, W. H., & Sokolove, J. (2019). Fibroblast-like synovial cell production of extra domain A fibronectin associates with inflammation in osteoarthritis. BMC rheumatology, 346. https://doi.org/10.1186/s41927-019-0093-4
Kragstrup, Tue W, et al. "Fibroblast-like synovial cell production of extra domain A fibronectin associates with inflammation in osteoarthritis." BMC rheumatology vol. 3 (2019): 46. doi: https://doi.org/10.1186/s41927-019-0093-4
Kragstrup TW, Sohn DH, Lepus CM, Onuma K, Wang Q, Robinson WH, Sokolove J. Fibroblast-like synovial cell production of extra domain A fibronectin associates with inflammation in osteoarthritis. BMC Rheumatol. 2019 Dec 02;3:46. doi: 10.1186/s41927-019-0093-4. eCollection 2019. PMID: 31819923; PMCID: PMC6886182.
Copy Download .nbib Format: NLM
Share it on

BMC Rheumatol. 2019 Dec 02;3:46. doi: 10.1186/s41927-019-0093-4. eCollection 2019.

Fibroblast-like synovial cell production of extra domain A fibronectin associates with inflammation in osteoarthritis.

BMC rheumatology

Tue W Kragstrup, Dong H Sohn, Christin M Lepus, Kazuhiro Onuma, Qian Wang, William H Robinson, Jeremy Sokolove

Affiliations

  1. 1Department of Immunology and Rheumatology, Stanford University, Stanford, CA USA.
  2. 2VA Palo Alto Health Care System, Palo Alto, CA USA.
  3. 3Department of Biomedicine, Aarhus University, Wilhelm Meyers Allé 4, DK-8000 Aarhus C, Denmark.
  4. 4Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark.
  5. 5Department of Microbiology and Immunology, Pusan National University School of Medicine, Yangsan, Republic of Korea.

PMID: 31819923 PMCID: PMC6886182 DOI: 10.1186/s41927-019-0093-4

Abstract

BACKGROUND: The pathophysiology of osteoarthritis (OA) involves wear and tear, and a state of low-grade inflammation. Tissue repair responses include transforming growth factor beta (TGFβ)-induced myofibroblast production of extracellular matrix. Fibronectins are an essential part of the extracellular matrix, and injection of fibronectin fragments into rabbit joints is a previously established animal model of OA. Fibronectin containing the ED-A domain is currently being used as drug delivery target in the development of anti-inflammatory drugs (e.g. Dekavil).

METHODS: In this study, samples of synovial membrane were obtained from patients with knee OA undergoing joint replacement surgery. Immunostaining for ED-A fibronectin and the myofibroblast marker alpha smooth muscle actin (αSMA) was performed on fibroblast-like synovial cells (FLS) and synovial membranes. RAW 264.7 macrophages were incubated with recombinant ED-A fibronectin.

RESULTS: The staining of ED-A fibronectin in OA FLS was increased by TGFβ but not by TNFα, lipopolysaccharide, or IL-6 (

CONCLUSIONS: The disease process in OA shares features with the chronic wound healing response. Our findings support utilizing ED-A fibronectin for drug delivery or therapeutic targeting to reduce pro-inflammatory responses in OA.

© The Author(s) 2019.

Keywords: Arthritis; Drug delivery; Fibronectin; Inflammation; Myofibroblast; Osteoarthritis; Synoviocyte; Synovitis

Conflict of interest statement

Competing interestsThe authors declare that they have no competing interests.

References

  1. IUBMB Life. 2011 Jul;63(7):538-46 - PubMed
  2. Osteoarthritis Cartilage. 2002 Nov;10(11):831-5 - PubMed
  3. Semin Arthritis Rheum. 2000 Feb;29(4):252-65 - PubMed
  4. Curr Opin Rheumatol. 2008 Sep;20(5):565-72 - PubMed
  5. Arthritis Rheum. 2003 Dec;48(12):3442-51 - PubMed
  6. Arch Biochem Biophys. 1996 Oct 15;334(2):325-31 - PubMed
  7. Clin Exp Rheumatol. 1996 Mar-Apr;14(2):155-62 - PubMed
  8. Rheumatol Int. 2004 Jan;24(1):25-33 - PubMed
  9. Nat Rev Rheumatol. 2016 Oct;12(10):580-92 - PubMed
  10. Ann Rheum Dis. 2017 May;76(5):914-922 - PubMed
  11. J Mol Med (Berl). 2017 Jul;95(7):779-787 - PubMed
  12. Rheumatology (Oxford). 2001 Jul;40(7):721-3 - PubMed
  13. Isr Med Assoc J. 2014 Oct;16(10):666 - PubMed
  14. J Orthop Res. 2014 Jun;32(6):811-8 - PubMed
  15. J Leukoc Biol. 2010 Jun;87(6):989-99 - PubMed
  16. J Cell Biol. 2003 Jul 7;162(1):149-60 - PubMed
  17. J Rheumatol. 1993 Aug;20(8):1378-82 - PubMed
  18. J Biol Chem. 1999 Oct 22;274(43):30756-63 - PubMed
  19. Arthritis Rheum. 1986 Aug;29(8):1039-49 - PubMed
  20. Ann Rheum Dis. 1957 Dec;16(4):494-502 - PubMed
  21. Arthritis Res Ther. 2014 Feb 04;16(1):R42 - PubMed
  22. Rheumatology (Oxford). 2001 Jul;40(7):739-42 - PubMed
  23. J Cell Biol. 1989 Aug;109(2):903-14 - PubMed
  24. Arthritis Res Ther. 2009;11(5):R142 - PubMed
  25. Ther Adv Musculoskelet Dis. 2013 Apr;5(2):77-94 - PubMed
  26. Clin Exp Immunol. 2017 Sep;189(3):342-351 - PubMed
  27. BMC Rheumatol. 2018 Nov 19;2:33 - PubMed
  28. Ann Rheum Dis. 2007 Dec;66(12):1599-603 - PubMed
  29. Arthritis Rheum. 1995 May;38(5):678-83 - PubMed
  30. Biochim Biophys Acta. 1993 Jan 22;1180(3):283-8 - PubMed
  31. J Cell Biol. 1998 Aug 10;142(3):873-81 - PubMed
  32. J Orthop Res. 2015 Apr;33(4):556-62 - PubMed
  33. Rheumatol Int. 2009 Oct;29(12):1397-401 - PubMed
  34. J Rheumatol. 1992 Sep;19(9):1448-52 - PubMed
  35. Adv Drug Deliv Rev. 2016 Feb 1;97:101-10 - PubMed
  36. J Biol Chem. 2001 Mar 30;276(13):10229-33 - PubMed

Publication Types